Dorzopt plus for glaucoma: instructions for use,

Eye drops Dorzopt plus is an antiglaucoma drug.

The composition, which includes two active components, namely: dorsalamide and timolol, helps to reduce intraocular pressure, by suppressing the production of intraocular fluid. When the interaction of these two components occurs, reducing the risk of inflammation.

On this page you will find all the information about Dorzopt: complete instructions for use for this drug, average prices in pharmacies, complete and incomplete analogues of the drug, as well as reviews of people who have already used Dorzopt Plus drops. Want to leave your opinion? Please write in the comments.

Clinico-pharmacological group

Antiglaucoma drug.

Pharmacy sales terms

It is released on prescription.


How much is Dorzopt plus? The average price in pharmacies is 700 rubles.

Release form and composition

Dorzopt Plus is made in the form of eye drops in the form of an almost colorless or colorless, transparent and slightly viscous solution (5 ml in a transparent or white polymer bottle dropper with a polymer cap and a safety ring, 1 bottle in a cardboard box).

  • The main elements: dorzolamide - 20 mg, timolol - 5 mg.

Additional components: benzalkonium chloride, purified water, mannitol, hyetillosis, 1 M sodium hydroxide solution / 1 M hydrochloric acid solution, 1 M sodium hydroxide solution, citric acid monohydrate.

Pharmacological effect

Antiglaucoma drug contains two active ingredients: dorzolamide and timolol, each of which reduces the increased intraocular pressure by reducing the secretion of intraocular fluid. The combined effect of these substances in the composition of the combined drug Dorzopt Plus leads to a more pronounced decrease in intraocular pressure.

  1. Timolol is a non-selective beta-blocker. Although the exact mechanism of action of timolol in reducing intraocular pressure has not yet been established, a number of studies have shown a predominant reduction in the formation of intraocular fluid, as well as a slight increase in its outflow.
  2. Dorzolamide is a selective type II carbonic anhydrase inhibitor. Inhibition of ciliary body carbonic anhydrase leads to a decrease in the secretion of intraocular fluid, presumably by reducing the formation of bicarbonate ions, which in turn leads to a slowdown in the transport of sodium and intraocular fluid.

The reduction in intraocular pressure occurs 20 minutes after instillation, reaches a maximum after 2 hours and lasts at least 24 hours.

Indications for use

Treatment with eye drops only on the recommendation of an ophthalmologist in the following cases:

  1. Glaucoma open-angle.
  2. Glaucoma pseudoexfoliative.
  3. With glaucoma.


According to the instructions, contraindications to the use of drops in the eyes are the following states:

  1. Patient age up to 18 years;
  2. Cardiogenic shock;
  3. A history of bronchial asthma;
  4. Acute myocardial infarction;
  5. Severe renal failure;
  6. Degenerative changes of the cornea;
  7. Individual intolerance to the components of the drug;
  8. Violation of cardiac conduction, change in heart rhythm;
  9. Heart failure in the stage of decompensation;
  10. Chronic obstructive pulmonary disease of severe course;
  11. Period of pregnancy and breastfeeding.

Drozopt Plus drops with extreme caution prescribed to patients with diabetes, liver failure or people of retirement age.

Use during pregnancy and lactation

In rat studies, the teratogenic effect of dorzolamide was established. Whether the substance penetrates into breast milk of lactating women has not been established, however, in young lactating female rats, a decrease in body weight gain has been observed.

Information on the use of timolol during pregnancy is not enough. In the course of epidemiological studies, no effect of beta-adrenergic blockers on the formation of congenital fetal defects was detected, but intrauterine growth retardation was detected. In addition, newborns whose mothers received beta-blockers before birth, were diagnosed with symptoms of blockade of beta-adrenoreceptors: hypoglycemia, arterial hypotension, bradycardia, respiratory failure. It is also known that beta-blockers penetrate into breast milk.

In view of the foregoing, the use of Dorsopt Plus during pregnancy and lactation is contraindicated. If you need the appointment of the drug to a nursing woman, you should stop breastfeeding.

Instructions for use

The instructions for use indicate that Dorzopt Plus is recommended to bury 1 drop in the conjunctival sac of the eye (or both eyes) 2 times / day.

  1. If the drug is prescribed as a substitute for another ophthalmic drug for the treatment of glaucoma, the latter must be canceled 1 day before the start of therapy with Doropt Plus.
  2. In case of joint use with other local ophthalmologic drugs, Dorzopt Plus administration of the drug should be carried out with an interval of 10 minutes.
  3. When nasolacrimal occlusion (closing of the eyelids) for 2 min after instillation of the drug decreases its systemic absorption, which can lead to increased local action.
  4. Dorzopt Plus is a sterile solution, so patients should be instructed how to use the bottle correctly.

The duration of treatment is determined by the doctor depending on the clinical condition of the patient.

Side effects

Side effect of the drug Dorzopt plus consists of the effects of active ingredients.


  1. Respiratory system: bronchospasm, chest pain, cough.
  2. Skin manifestations: exacerbations of psoriasis, alopecia, psoriasis-like rash.
  3. Allergy: angioedema, anaphylaxis, urticaria, rash (local and generalized).
  4. Cardiovascular system: hypotension, syncope, arrhythmia, cardiac arrest, Raynaud's syndrome, edema, decreased temperature of the legs and arms.
  5. Nervous system: paresthesia, ringing in the ears, pain in the head, fatigue, dizziness, asthenia, depression, nightmares, symptoms of myasthenia, memory loss, insomnia.
  6. Organs of vision: keratitis, decreased sensitivity of the corneal layer, blepharitis, conjunctivitis, dry eye cider, impaired vision, including those associated with changes in the refractive power of the eye, ptosis, diplopia.
  7. Digestive system: dry mouth, diarrhea, dyspepsia.


  1. Nervous system: headache, paresthesia, fatigue and asthenia.
  2. Allergy: bronchospasm, itching, angioedema, urticaria.
  3. Vision organs: lacrimation, iridocyclitis, inflammation, peeling, eyelid irritation, punctate keratitis, transient myopia, which disappears after discontinuation of the drug.
  4. Other: nosebleed, dry mouth, pharynx irritation, rash.


With prolonged use of the drug or exceeding the dose specified in the instructions, the patient develops symptoms of overdose, which manifest an increase in the above-described side effects, as well as inhibition of the function of the heart, liver, and kidneys. Possible cardiac arrest.

Against the background of an overdose with Dorzopt eye drops, patients often develop acidosis, changes in water-salt balance.

The treatment is aimed at eliminating the symptoms that have occurred and maintaining the normal functioning of the affected organs and body systems. It is necessary to control the concentration of electrolytes (especially sodium) and the pH of blood plasma. Dialysis is ineffective.

Special instructions

Dorzopt Plus, like other ophthalmic preparations for local use, can penetrate into the systemic circulation. Since timolol is a beta-blocker in the preparation, adverse reactions that develop with the systemic use of beta-blockers can be noted when Dorsopt Plus is used topically.

  1. Before using Dorzopt Plus, it is necessary to ensure adequate monitoring of the cardiovascular system.
  2. There have been reports of cases of heart failure with a fatal outcome with the use of timolol in the form of eye drops.
  3. At the first signs or symptoms of heart failure, the use of the drug Dorzopt Plus must be stopped.
  4. There have been reports of cases of bronchospasm with a fatal outcome in patients with asthma while using timolol in the form of eye drops.
  5. Patients with heart block I degree should be given beta-blockers with caution because of their ability to slow impulse conduction.
  6. The drug should be used with caution in patients with severe peripheral circulatory disorders (severe forms of the disease or Raynaud's syndrome).
  7. In patients with mild to moderate COPD, Dorzopt Plus should be used with caution and only if the intended benefit of treatment outweighs the potential risk.
  8. The drug should be used with caution in patients with spontaneous hypoglycemia or in patients with diabetes mellitus (especially with a labile course) while using insulin or oral hypoglycemic drugs, since beta-blockers may mask the symptoms of hypoglycemia.
  9. The need to cancel beta-blockers in the case of the upcoming extensive surgical intervention has not been proven. The effects of beta-blockers during the operation, if necessary, can be eliminated by applying sufficient doses of adrenergic mimetics.
  10. Beta-blockers may mask some clinical signs of hyperthyroidism (for example, tachycardia). If hyperthyroidism is suspected, patients should be closely monitored. It is necessary to avoid abrupt withdrawal of beta-blockers due to the risk of a thyrotoxic crisis.
  11. Like other ophthalmic preparations for topical use, Dorzopt Plus can penetrate the systemic circulation. Dorzolamide is a sulfanilamide. Adverse reactions identified with the systemic use of sulfonamides can be observed when the drug is applied topically (Stevens-Johnson syndrome and toxic epidermal necrolysis). If there are signs of serious hypersensitivity reactions, the drug should be stopped. In the treatment of beta-adrenergic blockers in patients with atopy or severe anaphylactic reactions to various allergens in the anamnesis, it is possible to enhance the response upon repeated contact with these allergens. In this group of patients, the use of epinephrine in the standard therapeutic dose for the relief of allergic reactions may be ineffective.
  12. Studies of the use of the drug Dorzopt Plus in patients with liver failure have not been conducted, so the drug in these patients should be used with caution.
  13. Beta-blockers used in ophthalmology can cause dry eye mucosa. In patients with corneal disorders, the drug should be used with caution. Patients with a low number of endothelial cells have an increased risk of corneal edema.
  14. When using the drug Dorzopt Plus in patients taking systemic beta-blockers, it is necessary to take into account the possible mutual enhancement of the pharmacological action of the drugs, both in terms of the known systemic effects of beta-blockers, and in the reduction of intraocular pressure. The combined use of the drug Dorzopt Plus with other beta-blockers is not recommended.
  15. If you need to cancel the topical application of timolol, as in the case of the abolition of systemic beta-blockers, discontinuation of therapy in patients with coronary artery disease should be carried out gradually.
  16. In clinical studies, the difference in the efficacy and safety of the dorzolamide + timolol combination in patients over 65 years of age compared with younger patients was not detected. However, one should not exclude the possibility of a higher sensitivity to the drug in some elderly patients.
  17. The use of systemic carbonic anhydrase inhibitors can lead to an imbalance of acid-base balance and can be accompanied by urolithiasis, especially in patients with history of urolithiasis. The composition of the drug Dorzopt Plus is a carbonic anhydrase inhibitor, which, when applied topically, can be absorbed and enter the systemic circulation, therefore the risk of urolithiasis in patients with urolithiasis in history with Dorzopt Plus treatment may increase.
  18. Dorzopt Plus contains a preservative benzalkonium chloride, which can be a cause of eye irritation. Therefore, before using the drug, patients should remove the soft contact lenses and install them back no earlier than 15 minutes after instillation of the drug. Benzalkoniya chloride can discolor soft contact lenses.

During the period of use of the drug Dorzopt Plus, it is necessary to refrain from driving vehicles and mechanisms and practicing potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.

Drug interactions

  1. With Acetazolamide - increased risk of systemic adverse reactions.
  2. With large doses of acetylsalicylic acid is likely to increase toxicity.
  3. The combination with antiglaucoma drugs (β-blockers, Pilocarpine, Dipivefrin, Carbachol) causes an increase in the effect of Dorzolamide.


We picked up some people reviews about the drug Dorzopt plus:

  1. Stas. After taking the drug Dorzopt plus left mixed impressions. With its immediate responsibilities drug coped. Its price is relatively inexpensive again. But I had several possible side effects and I didn’t like it at all!

Consumer reviews about the considered tool is not very much. The advantages of this medication include high efficiency and effectiveness, as well as availability (sold in almost any pharmacy).

It should also be noted that Dorzopt Plus drops also have negative responses from patients. Many of them complain that after applying a local remedy, local or systemic adverse reactions are quite common. Therefore, experts do not recommend using the above drug alone. To achieve the best therapeutic result, he should be appointed only by an experienced doctor. Only with a properly chosen treatment regimen can side effects be avoided.


Structural analogues of the active substance:

  • Dorzolamide hydrochloride;
  • Dorzopt Plus;
  • Kosopt;
  • Trusopt.

Before using analogues consult your doctor.

Storage conditions and shelf life

Drops should be stored at room temperature out of the reach of children, avoiding heating or freezing. If any suspended matter or impurities appear in the vial, drops should be discarded, even if the drug has not expired.

After opening the bottle can be used for 4 weeks.Provided the integrity of the packaging - up to 2 years.

Watch the video: Glaucoma. Ингибиторы карбоангидразы в терапии глаукомы, 1, Голубев . (April 2020).


Leave Your Comment